Which company produces acotinib/acalabrutinib?

Acalabrutinib/Acalabrutinib (Acalabrutinib) is developed and produced by the American pharmaceutical company (Acerta Pharma). Acerta is a biopharmaceutical company focused on developing innovative oncology treatments, particularly in the area of u200bu200btargeted therapies. The development of acotinib began with Acerta and was later acquired by AstraZeneca, a world-renowned pharmaceutical company. AstraZeneca is a multinational pharmaceutical company committed to delivering innovative medicines to patients around the world. Acotinib has become one of AstraZeneca's important products in the field of hematological cancer treatment and further strengthened the company's business layout in the field of oncology treatment.

The production and marketing of acotinib is based on the research and development results of Acerta Pharmaceuticals. The drug is a selective Bruton's tyrosine kinase (BTK) inhibitor, mainly used to treat chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and other B cell-related hematological malignancies. The successful launch of acotinib marks Acerta Pharmaceuticals' achievements in the development of targeted drugs and also reflects AstraZeneca's strategy to expand its oncology treatment areas globally.

During the development process of acotinib, Acerta Pharmaceuticals focused on the selectivity and tolerability of the drug, aiming to provide better therapeutic effects and lower risk of adverse reactions than traditional BTK inhibitors (such as ibrutinib). Compared with traditional drugs, acotinib has higher targeting, can inhibit BTK more accurately, and reduces the inhibitory effect on other non-targeted kinases, thereby reducing common adverse reactions during treatment, such as bleeding and arrhythmia. Therefore, acotinib has become one of the first-choice drugs for the treatment of diseases such as chronic lymphocytic leukemia and mantle cell lymphoma.

Through the R&D of Acerta Pharmaceuticals and AstraZeneca's global sales network, acotinib has been approved in many countries and is widely used in clinical applications, becoming an important innovative drug in the treatment of lymphatic system malignancies.

Reference materials:https://www.calquence.com/